Literature DB >> 28177989

Accuracy of MRI in Restaging Locally Advanced Rectal Cancer After Preoperative Chemoradiation.

Joris J van den Broek1, Floor S W van der Wolf, Max J Lahaye, Luc A Heijnen, Christof Meischl, Martin A Heitbrink, W Hermien Schreurs.   

Abstract

BACKGROUND: Patients with a locally advanced rectal carcinoma benefit from preoperative chemoradiotherapy. MRI is considered the first choice imaging modality after preoperative chemoradiation, although its reliability for restaging is debatable.
OBJECTIVE: The purpose of this study was to determine the accuracy of MRI in restaging locally advanced rectal cancer after preoperative chemoradiation.
DESIGN: This was a retrospective study. SETTINGS: The study was conducted in a Dutch high-volume rectal cancer center. PATIENTS: A consecutive cohort of 48 patients with locally advanced rectal cancer treated with a curative intent was identified. MAIN OUTCOME MEASURES: Three readers independently evaluated the MRI both for primary staging and for restaging after preoperative chemoradiation and were blinded to results from the other readers as well as histological results. Interobserver variability was determined. Accuracy of the restaging MRI was assessed through the comparison of tumor characteristics on MRI with histopathologic outcomes.
RESULTS: T stage was correctly predicted by the 3 readers in 47% to 68% and N stage in 68% to 70%. Overstaging was more common than understaging. Positive predictive values (PPV) among the 3 readers for T0 were 0%, and negative predictive values (NPVs) varied from 84% to 85%. For T1/2, PPVs and NPVs were 50% to 67% and 72% to 90%, and for T3/4 they were 54% to 62% and 33% to 78%. PPVs and NPVs for N0 stage were 81% to 95% and 58% to 73%. Tumor regression grade on MRI did not correspond with histopathologic tumor regression grade; PPVs for good response (tumor regression grade on MRI 1-2) were 48% to 61%, and NPVs were 42% to 58%. Interobserver agreement was fair to moderate for T stage, N stage, and tumor response (κ = 0.20-0.41) and fair to substantial for the relation with the mesorectal fascia (κ = 0.33-0.77). In none of the patients was the surgical plan changed after the restaging MRI. LIMITATIONS: This study was limited by its small sample size and retrospective nature.
CONCLUSIONS: MRI has low accuracy for restaging locally advanced rectal cancer after preoperative chemoradiation, and the interobserver variability is significant.

Entities:  

Mesh:

Year:  2017        PMID: 28177989     DOI: 10.1097/DCR.0000000000000743

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  18 in total

1.  Utility of MR imaging in the evaluation of colon cancer: emphasis on distinguishing tumor tissue from fibrosis and role of contrast media.

Authors:  Akitoshi Inoue; Shinichi Ohta; Norihisa Nitta; Masahiro Yoshimura; Tomoharu Shimizu; Masaji Tani; Ryoji Kushima; Kiyoshi Murata
Journal:  Jpn J Radiol       Date:  2017-05-20       Impact factor: 2.374

2.  MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Authors:  Natally Horvat; Harini Veeraraghavan; Monika Khan; Ivana Blazic; Junting Zheng; Marinela Capanu; Evis Sala; Julio Garcia-Aguilar; Marc J Gollub; Iva Petkovska
Journal:  Radiology       Date:  2018-03-07       Impact factor: 11.105

3.  MRI at Restaging After Neoadjuvant Therapy for Rectal Cancer Overestimates Circumferential Resection Margin Proximity as Determined by Comparison With Whole-Mount Pathology.

Authors:  Jonathan B Yuval; Hannah M Thompson; Canan Firat; Floris S Verheij; Maria Widmar; Iris H Wei; Emmanouil Pappou; J Joshua Smith; Martin R Weiser; Philip B Paty; Garrett M Nash; Jinru Shia; Marc J Gollub; Julio Garcia-Aguilar
Journal:  Dis Colon Rectum       Date:  2022-04-01       Impact factor: 4.585

4.  A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer.

Authors:  Xiaolin Pang; Peiyi Xie; Li Yu; Haiyang Chen; Jian Zheng; Xiaochun Meng; Xiangbo Wan
Journal:  Br J Cancer       Date:  2022-04-06       Impact factor: 9.075

5.  The prognostic importance of MRI detected extramural vascular invasion (mrEMVI) in locally advanced rectal cancer.

Authors:  J J van den Broek; F S W van der Wolf; L A Heijnen; W H Schreurs
Journal:  Int J Colorectal Dis       Date:  2020-06-02       Impact factor: 2.571

6.  MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy.

Authors:  Jong Keon Jang; Sang Hyun Choi; Seong Ho Park; Kyung Won Kim; Hyun Jin Kim; Jong Seok Lee; Ah Young Kim
Journal:  Eur Radiol       Date:  2020-01-17       Impact factor: 5.315

7.  Accuracy of MRI for nodal restaging in rectal cancer: a retrospective study of 166 cases.

Authors:  Sayali Pangarkar; Kunal Mistry; Amit Choudhari; Vasundhara Smriti; Ankita Ahuja; Aparna Katdare; Reena Engineer; Vikas Ostwal; Mukta Ramadwar; Avanish Saklani; Akshay D Baheti
Journal:  Abdom Radiol (NY)       Date:  2020-08-19

8.  Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.

Authors:  Francesco Sclafani; Gina Brown; David Cunningham; Andrew Wotherspoon; Larissa Sena Teixeira Mendes; Svetlana Balyasnikova; Jessica Evans; Clare Peckitt; Ruwaida Begum; Diana Tait; Josep Tabernero; Bengt Glimelius; Susana Roselló; Janet Thomas; Jacqui Oates; Ian Chau
Journal:  Br J Cancer       Date:  2017-09-21       Impact factor: 7.640

9.  MRI accuracy and interobserver agreement in locally advanced cervix carcinoma.

Authors:  Amalia Jacquot; Céline Chauleur; Anne-Sophie Russel-Robillard; Fabien Tinquaut; Sandrine Sotton; Nicolas Magne; Guillaume Etievent
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

10.  Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer.

Authors:  Marco Rengo; Simona Picchia; Simona Marzi; Davide Bellini; Damiano Caruso; Mauro Caterino; Maria Ciolina; Domenico De Santis; Daniela Musio; Vincenzo Tombolini; Andrea Laghi
Journal:  Oncotarget       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.